T-2 produced very positive results, better than the results produced by any antirheumatic drug. ❋ Dr. Kenneth R. Pelletier (2000)
On October 17, 2009, Genentech and Biogen Idec announced that the companies received a complete response letter from the FDA for a supplemental Biologics License Application (sBLA) for RITUXAN plus MTX in patients with moderately-to-severely active rheumatoid arthritis (RA) who no longer respond to treatment with a disease modifying antirheumatic drug (DMARD), including MTX. ❋ Editors (2010)
The classification criteria for rheumatoid arthritis are unhelpful in the early stages of the disease, but the need for disease modifying antirheumatic drugs can be accurately predicted by clinical and laboratory ❋ Unknown (2010)
Drugs that help control disease and limit joint damage, which include disease-modifying antirheumatic drugs (DMARDs) and biologic-response modifiers (biologics). ❋ Unknown (2010)
Some disease-modifying antirheumatic drugs (DMARDs) that have been around for decades. ❋ Unknown (2010)
It also has antibiotic and antirheumatic properties and is very useful in the treatment of digestive sluggishness, especially after following an overly rich and unhealthy diet. ❋ Unknown (2010)
It is classified as a disease-modifying antirheumatic drug or DMARD. ❋ Unknown (2010)
We focus on varying diseases relating to respiratory system, digestive system, cardio-cerebral vascular system, antineoplastic, bone diseases-modifying antirheumatic, gynecological, and refill nutrition, among others. ❋ Unknown (2010)
Over the forecast period, the GI market's growth will be determined by the growth of the immunosuppressants and antirheumatic agents. ❋ Unknown (2010)
Sullivan's expert analysts thoroughly examine the following markets: disease-modifying antirheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), and biologics. ❋ Editors (2010)
Patients were allowed to continue nonsteroidal antiinflammatory drugs (NSAID) and disease modifying antirheumatic drugs (DMARD) during the study. ❋ Patricktan988 (2010)
& Sullivan's expert analysts thoroughly examine the following markets: disease-modifying antirheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), and biologics. ❋ Unknown (2010)
Methotrexate (MTX), a folate antagonist that blocks folic acid activity, is the most widely used disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis. ❋ Unknown (2009)
Traditional treatments for RA include non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids and disease-modifying antirheumatic drugs (DMARDs), with biological therapies a more recent addition. ❋ Unknown (2009)
Disease-modifying antirheumatic drugs 3: methotrexate. ❋ Unknown (2009)
